1RCT1994
Mauri M, Sinforiani E, Reverberi F, Merlo P, Bono G · Arch Gerontol Geriatr (1994)
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
5 peer-reviewed studies
What the evidence says
Most Pramiracetam studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 1985–1994 with a typical study size of 10 participants.
Based on 5 studies · 4 RCTs · 10 total participants
Confidence
Moderate confidenceBy outcome
Newest study from 1994
Mauri M, Sinforiani E, Reverberi F, Merlo P, Bono G · Arch Gerontol Geriatr (1994)
Chang T, Young RM, Goulet JR, Yakatan GJ · J Clin Pharmacol (1985)
McLean A, Cardenas DD, Burgess D, Gamzu E · Brain Inj (1991)
In plain English: Some benefit in clinical studies with patients suffering from mild to moderate degrees of dementia has been demonstrated, but no generally accepted mechanism of action has emerged.
Gouliaev AH, Senning A. · Brain Res Brain Res Rev (1994)
In plain English: Doses up to 4,000 mg pramiracetam are unlikely to confer symptomatic benefit to Alzheimer's disease patients.
Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN. · Neurology (1991)